Literature DB >> 25292429

Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers.

Henry M Dunnenberger1, Kristine R Crews, James M Hoffman, Kelly E Caudle, Ulrich Broeckel, Scott C Howard, Robert J Hunkler, Teri E Klein, William E Evans, Mary V Relling.   

Abstract

Although the field of pharmacogenetics has existed for decades, practioners have been slow to implement pharmacogenetic testing in clinical care. Numerous publications describe the barriers to clinical implementation of pharmacogenetics. Recently, several freely available resources have been developed to help address these barriers. In this review, we discuss current programs that use preemptive genotyping to optimize the pharmacotherapy of patients. Array-based preemptive testing includes a large number of relevant pharmacogenes that impact multiple high-risk drugs. Using a preemptive approach allows genotyping results to be available prior to any prescribing decision so that genomic variation may be considered as an inherent patient characteristic in the planning of therapy. This review describes the common elements among programs that have implemented preemptive genotyping and highlights key processes for implementation, including clinical decision support.

Entities:  

Keywords:  clinical decision support; individualized medicine; personalized medicine; pharmacogenomics; precision medicine; prediction in pharmacology

Mesh:

Year:  2014        PMID: 25292429      PMCID: PMC4607278          DOI: 10.1146/annurev-pharmtox-010814-124835

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  72 in total

1.  Integration of genetic, clinical, and INR data to refine warfarin dosing.

Authors:  P Lenzini; M Wadelius; S Kimmel; J L Anderson; A L Jorgensen; M Pirmohamed; M D Caldwell; N Limdi; J K Burmester; M B Dowd; P Angchaisuksiri; A R Bass; J Chen; N Eriksson; A Rane; J D Lindh; J F Carlquist; B D Horne; G Grice; P E Milligan; C Eby; J Shin; H Kim; D Kurnik; C M Stein; G McMillin; R C Pendleton; R L Berg; P Deloukas; B F Gage
Journal:  Clin Pharmacol Ther       Date:  2010-04-07       Impact factor: 6.875

2.  The path to personalized medicine.

Authors:  Margaret A Hamburg; Francis S Collins
Journal:  N Engl J Med       Date:  2010-06-15       Impact factor: 91.245

Review 3.  Anticipating clinical integration of pharmacogenetic treatment strategies for addiction: are primary care physicians ready?

Authors:  A E Shields; C Lerman
Journal:  Clin Pharmacol Ther       Date:  2008-03-05       Impact factor: 6.875

4.  PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics.

Authors:  James M Hoffman; Cyrine E Haidar; Mark R Wilkinson; Kristine R Crews; Donald K Baker; Nancy M Kornegay; Wenjian Yang; Ching-Hon Pui; Ulrike M Reiss; Aditya H Gaur; Scott C Howard; William E Evans; Ulrich Broeckel; Mary V Relling
Journal:  Am J Med Genet C Semin Med Genet       Date:  2014-03-11       Impact factor: 3.908

5.  Challenges in implementing genomic medicine: the Mayo Clinic Center for Individualized Medicine.

Authors:  G Farrugia; R M Weinshilboum
Journal:  Clin Pharmacol Ther       Date:  2013-03-11       Impact factor: 6.875

Review 6.  The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics.

Authors:  P H O'Donnell; A Bush; J Spitz; K Danahey; D Saner; S Das; N J Cox; M J Ratain
Journal:  Clin Pharmacol Ther       Date:  2012-08-29       Impact factor: 6.875

7.  Care patterns in Medicare and their implications for pay for performance.

Authors:  Hoangmai H Pham; Deborah Schrag; Ann S O'Malley; Beny Wu; Peter B Bach
Journal:  N Engl J Med       Date:  2007-03-15       Impact factor: 91.245

8.  Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.

Authors:  S A Scott; K Sangkuhl; C M Stein; J-S Hulot; J L Mega; D M Roden; T E Klein; M S Sabatine; J A Johnson; A R Shuldiner
Journal:  Clin Pharmacol Ther       Date:  2013-05-22       Impact factor: 6.875

9.  Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing.

Authors:  S L Van Driest; Y Shi; E A Bowton; J S Schildcrout; J F Peterson; J Pulley; J C Denny; D M Roden
Journal:  Clin Pharmacol Ther       Date:  2013-11-19       Impact factor: 6.875

10.  Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process.

Authors:  Kelly E Caudle; Teri E Klein; James M Hoffman; Daniel J Muller; Michelle Whirl-Carrillo; Li Gong; Ellen M McDonagh; Katrin Sangkuhl; Caroline F Thorn; Matthias Schwab; Jose A G Agundez; Robert R Freimuth; Vojtech Huser; Ming Ta Michael Lee; Otito F Iwuchukwu; Kristine R Crews; Stuart A Scott; Mia Wadelius; Jesse J Swen; Rachel F Tyndale; C Michael Stein; Dan Roden; Mary V Relling; Marc S Williams; Samuel G Johnson
Journal:  Curr Drug Metab       Date:  2014-02       Impact factor: 3.731

View more
  165 in total

1.  Standardized Biogeographic Grouping System for Annotating Populations in Pharmacogenetic Research.

Authors:  Rachel Huddart; Alison E Fohner; Michelle Whirl-Carrillo; Genevieve L Wojcik; Christopher R Gignoux; Alice B Popejoy; Carlos D Bustamante; Russ B Altman; Teri E Klein
Journal:  Clin Pharmacol Ther       Date:  2019-01-21       Impact factor: 6.875

2.  Value of Genetics-informed Drug Dosing Guidance in Pregnant Women: A Needs Assessment with Obstetric Healthcare Providers at Johns Hopkins.

Authors:  Casey L Overby; Phillip Thompkins; Harold Lehmann; Christopher G Chute; Jeanne S Sheffield
Journal:  AMIA Annu Symp Proc       Date:  2018-04-16

3.  Role of Preemptive Genotyping in Preventing Serious Adverse Drug Events in South Korean Patients.

Authors:  Grace Juyun Kim; Soo Youn Lee; Ji Hye Park; Brian Y Ryu; Ju Han Kim
Journal:  Drug Saf       Date:  2017-01       Impact factor: 5.606

4.  Current practices in the delivery of pharmacogenomics: Impact of the recommendations of the Pharmacy Practice Model Summit.

Authors:  John Valgus; Kristin W Weitzel; Josh F Peterson; Daniel J Crona; Christine M Formea
Journal:  Am J Health Syst Pharm       Date:  2019-04-08       Impact factor: 2.637

Review 5.  Value of Supportive Care Pharmacogenomics in Oncology Practice.

Authors:  Jai N Patel; Lauren A Wiebe; Henry M Dunnenberger; Howard L McLeod
Journal:  Oncologist       Date:  2018-04-05

6.  Clinical Pharmacogenomics: Applications in Nephrology.

Authors:  Solomon M Adams; Karryn R Crisamore; Philip E Empey
Journal:  Clin J Am Soc Nephrol       Date:  2018-05-23       Impact factor: 8.237

7.  Is your love in vain? On associations between genotypes, drug concentrations and clinical outcomes in pharmacogenomic research.

Authors:  Per Damkier
Journal:  Int J Clin Pharm       Date:  2015-07-17

8.  Longitudinal exposure of English primary care patients to pharmacogenomic drugs: An analysis to inform design of pre-emptive pharmacogenomic testing.

Authors:  James E Kimpton; Iain M Carey; Christopher J D Threapleton; Alexandra Robinson; Tess Harris; Derek G Cook; Stephen DeWilde; Emma H Baker
Journal:  Br J Clin Pharmacol       Date:  2019-12-13       Impact factor: 4.335

9.  A pilot study of the implementation of pharmacogenomic pharmacist initiated pre-emptive testing in primary care.

Authors:  Paul C D Bank; Jesse J Swen; Rowena D Schaap; Daniëlle B Klootwijk; Renée Baak-Pablo; Henk-Jan Guchelaar
Journal:  Eur J Hum Genet       Date:  2019-06-21       Impact factor: 4.246

10.  How to Transition from Single-Gene Pharmacogenetic Testing to Preemptive Panel-Based Testing: A Tutorial.

Authors:  Richard J Marrero; Emily J Cicali; Meghan J Arwood; Elizabeth Eddy; David DeRemer; Brian H Ramnaraign; Karen C Daily; Dennie Jones; Kelsey J Cook; Larisa H Cavallari; Kristin Wiisanen Weitzel; Taimour Langaee; Kimberly J Newsom; Petr Starostik; Michael J Clare-Salzer; Julie A Johnson; Thomas J George; Rhonda M Cooper-DeHoff
Journal:  Clin Pharmacol Ther       Date:  2020-07-06       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.